Morgan Stanley Arcus Biosciences, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 714,456 shares of RCUS stock, worth $10.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

714,456

Previous 445,880 60.24%

Holding current value

$10.1 Million

Previous $6.79 Million 60.88%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $3.68 Million - $4.84 Million	268,576 Added 60.24%	714,456 $10.9 Million
Q2 2024 Oct 17, 2024	SELL	$14.59 - $18.48 $6.26 Million - $7.93 Million	-429,002 Reduced 49.04%	445,880 $6.79 Million
Q2 2024 Aug 14, 2024	SELL	$14.59 - $18.48 $6.26 Million - $7.93 Million	-429,002 Reduced 49.04%	445,880 $6.79 Million
Q1 2024 Oct 17, 2024	BUY	$14.83 - $20.18 $6.36 Million - $8.66 Million	429,002 Added 96.21%	874,882 $16.5 Million
Q1 2024 Aug 16, 2024	BUY	$14.83 - $20.18 $2.57 Million - $3.5 Million	173,487 Added 24.73%	874,882 $16.5 Million
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $2.57 Million - $3.5 Million	173,487 Added 24.73%	874,882 $16.5 Million
Q4 2023 Aug 16, 2024	BUY	$13.43 - $19.63 $3.43 Million - $5.02 Million	255,515 Added 57.31%	701,395 $13.4 Million
Q4 2023 Feb 13, 2024	BUY	$13.43 - $19.63 $1.24 Million - $1.81 Million	92,409 Added 15.17%	701,395 $13.4 Million
Q3 2023 Nov 15, 2023	SELL	$17.62 - $23.54 $203,475 - $271,839	-11,548 Reduced 1.86%	608,986 $10.9 Million
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $1.09 Million - $1.42 Million	64,453 Added 11.59%	620,534 $12.6 Million
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $155,322 - $225,295	9,732 Added 1.78%	556,081 $10.1 Million
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $3.81 Million - $6.9 Million	193,288 Added 54.75%	546,349 $11.3 Million
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $5.36 Million - $6.94 Million	-230,635 Reduced 39.51%	353,061 $9.24 Million
Q2 2022 Oct 27, 2022	BUY	$17.23 - $37.73 $5.74 Million - $12.6 Million	333,066 Added 132.89%	583,696 $14.8 Million
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $5.74 Million - $12.6 Million	333,066 Added 132.89%	583,696 $14.8 Million
Q1 2022 Oct 27, 2022	SELL	$28.92 - $41.83 $9.63 Million - $13.9 Million	-333,066 Reduced 57.06%	250,630 $7.91 Million
Q1 2022 May 13, 2022	SELL	$28.92 - $41.83 $34.2 Million - $49.5 Million	-1,183,774 Reduced 82.53%	250,630 $7.91 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $40.8 Million - $63 Million	1,300,591 Added 971.95%	1,434,404 $58 Million
Q3 2021 Nov 15, 2021	BUY	$26.93 - $37.68 $3.6 Million - $5.04 Million	133,813 New	133,813 $4.67 Million

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account